If SHP2 inhibition combines synergistically with ALK inhibition to reduce tumour cell growth, then SHP2 inhibitors might improve outcomes with alectinib in ALK+ NSCLC at sub-toxic doses of SHP2 inhibition. Here, ALK is linked to non-small cell lung carcinoma.